Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Q-011
- Development stage
- Preclinical
- Lead developer
- Uniquest
- Modality
- Small Molecules
01
Overview
Q-011 is a small molecule NLRP1 inhibitor being developed by the Queensland Emory Drug Discovery Initiative (QEDDI), a division of UniQuest. NLRP1 (NLR family pyrin domain containing 1) is a key component of the inflammasome, a multiprotein complex that triggers inflammatory responses by activating caspase-1 and promoting the release of pro-inflammatory cytokines such as IL-1β and IL-18. By inhibiting NLRP1, Q-011 aims to prevent inflammasome activation and is being investigated for the treatment of various inflammasome-related inflammatory disorders. The drug is currently in the lead optimization stage of preclinical development.
02
Targets
NLRP1 (NLR family pyrin domain containing 1)
Beyond the preview
Go deeper on Q-011.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Q-011.